 | |
| Clinical data | |
|---|---|
| Other names | Metaproterenol (USAN US) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682084 |
| Pregnancy category |
|
| Routes of administration |
Inhalation (MDI) and tablets |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 3% if inhaled, 40% if taken orally |
| Metabolism | Gastrointestinal and hepatic |
| Elimination half-life | 6 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.008.701 |
| Chemical and physical data | |
| Formula | C11H17NO3 |
| Molar mass | 211.261 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| Solubility in water | 9.7 mg/mL (20 °C) |
| |
| |
  (what is this?) (verify)
| |
Orciprenaline, also known as metaproterenol, is a bronchodilator used in the treatment of asthma. Orciprenaline is a moderately selective β2 adrenergic receptor agonist that stimulates receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal muscle, with minimal or no effect on α adrenergic receptors. The pharmacologic effects of β adrenergic agonist drugs, such as orciprenaline, are at least in part attributable to stimulation through β adrenergic receptors of intracellular adenylyl cyclase, the enzyme which catalyzes the conversion of ATP to cAMP. Increased cAMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from many cells, especially from mast cells.
Possible side effects
- tremor
- nervousness
- dizziness
- weakness
- headache
- nausea
- tachycardia
- Rare side effects that could be life-threatening
- increased difficulty breathing
- rapid or increased heart rate
- irregular heartbeat
- chest pain or discomfort
Brand names
- Alupent
- Metaprel
- Orcibest